Xencor Inc. (NASDAQ:XNCR) hit a new 52-week high on Monday . The stock traded as high as $23.30 and last traded at $23.03, with a volume of 220,118 shares. The stock had previously closed at $22.25.

XNCR has been the topic of several recent research reports. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Tuesday, July 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Xencor in a research note on Tuesday, May 3rd. TheStreet raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Monday, April 25th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Xencor in a research note on Monday, May 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xencor in a research note on Wednesday, June 29th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Xencor presently has an average rating of “Buy” and an average price target of $22.33.

The company’s 50 day moving average price is $18.90 and its 200 day moving average price is $14.25. The stock has a market cap of $941.83 million and a P/E ratio of 24.44.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $1.31. The firm had revenue of $66 million for the quarter, compared to analysts’ expectations of $7.43 million. On average, analysts anticipate that Xencor Inc. will post $0.72 earnings per share for the current year.

In related news, CEO Bassil I. Dahiyat sold 45,886 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $13.00, for a total value of $596,518.00. Following the sale, the chief executive officer now directly owns 358,186 shares of the company’s stock, valued at $4,656,418. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $21.83, for a total transaction of $54,575.00. Following the completion of the sale, the insider now directly owns 2,500 shares in the company, valued at $54,575. The disclosure for this sale can be found here.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.